Multicenter studies initiated in the United States typically have been reviewed by the institutional review board (IRB) of each participating center. This duplicative IRB review process has been criticized as costly, responsible for significant delays, and a hindrance to participant recruitment. 1, 2 Disparate requests from local IRBs and resulting modifications to study protocols can also alter the intended generalizability of study findings. 2 There are existing federal policies to reduce the number of IRBs reviewing multicenter studies, but this voluntary option is rarely used.
The National Institutes of Health (NIH) provides significant funding for biomedical research, approximately $32 billion per year. 3 In 2016, the NIH expended $12 billion for clinical research and $3.5 billion for clinical trials. 4 In an effort to lower research costs and eliminate the layers of ethical review that unduly delay and complicate the conduct of multicenter research, 5 the NIH proposed a policy (on June 21, 2016) for ethical review of multicenter research funded or conducted by the NIH. 6 U.S.-based centers leading NIHfunded multicenter research are expected to use a single institutional review board (sIRB) effective January 25, 2018. [6] [7] [8] Prior to the final policy, draft guidance and a request for public comments were issued on December 3, 2014. Public comments in response to the NIH draft policy were released on June 30, 2015. 9, 10 To understand the potential influence of the public comments on the final sIRB policy, we conducted a directed content analysis of the comments submitted in response to the NIH draft policy on implementation of sIRB review for multicenter studies. 10, 11 We summarize and appraise the comments, discuss if and how the final NIH policy addresses the public comments, and highlight concerns that require additional guidance.
Method
Two reviewers (A.M.E. and an external reviewer) independently evaluated the full text of all public comments, available online, 10 to assess whether respondents did or did not support the proposed policy or did not indicate support. Analyses were conducted between January and April 2016.
On the basis of prior work to identify research gaps that should be addressed prior to implementation of an sIRB mandate, 12 we specified four themes related to implementation of the NIH policy: criteria for selecting the sIRB; delineation of investigator, IRB, and institutional responsibilities; the cost of sIRB review; and consideration of local IRB reviews. One reviewer (A.M.E.) conducted an open text review of comments to determine the number that addressed the specified implementation themes and to assess whether the comments included additional themes that were not specified (between January and April 2016). A
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Purpose
In 2014, the National Institutes of Health (NIH) requested public comments on a draft policy requiring NIH-funded, U.S.-based investigators to use a single institutional review board (sIRB) for ethical review of multicenter studies. The authors conducted a directed content analysis and qualitative summary of the comments and discuss how they shaped the final policy.
Method
Two reviewers independently assessed support for the policy from a review of comments on the draft policy in 2016. A reviewer conducted an open text review to identify prespecified and additional comment themes. A second researcher reviewed 20% of comments; discrepancies were resolved through discussion.
Results
The NIH received 167 comments: 65% (108/167) supportive of the policy, 23% (38/167) not supportive, and 12% (21/167) not indicating support. Clarifications or changes to the policy were suggested in 102/167 comments (61%). Criteria for selecting sIRBs were addressed in 32/102 comments (31%). Also addressed were institutional review board (IRB) responsibilities (39/102; 38%), cost (27/102; 26%), the role of local IRBs (14/102; 14%), and allowable policy exceptions (19/102; 19%) . The NIH further clarified or provided guidance for selection criteria, IRB responsibilities, and cost in the final policy (June 2016). Local IRB reviews and exemptions guidance were unchanged.
Conclusions
In this case study, public comments were effective in shaping policy as the NIH modified provisions or planned supplemental guidance in response to comments. Yet critical knowledge gaps remain, and empirical data are necessary. The NIH is considering mechanisms to support the establishment of best practices for sIRB implementation.
Why Public Comments Matter: The Case of the National Institutes of Health Policy on Single Institutional Review Board Review of Multicenter Studies second reviewer (H.A.T.) conducted an open text review of a 20% random sample of the comments, identifying the specified themes and any additional themes specific to implementation of the policy. The second reviewer did not have knowledge of the first reviewer's classifications. We resolved all discrepancies by discussion.
We qualitatively summarized the themes that emerged from the public comments, with direct quotations included for illustrative purposes only. The responses to the public comments by the NIH in the final sIRB policy and any modifications or clarifications to the policy are also summarized. IRB approval was not required for this study.
Results
The NIH received 167 comments from December 3, 2014 In addition to the four specified implementation themes, one additional theme-exceptions to the sIRB policy-emerged from the reviews. We summarize public comments specific to implementation of the policy and the response to these comments by the NIH in the final sIRB policy in the following sections.
Of the 33 randomly selected public comments that we independently coded for the 5 relevant themes by 2 reviewers, 10 thematic coding discrepancies out of a possible 165 total options had to be discussed by the 2 reviewers (9 public comments; 6%). The reviewers each highlighted the sections of the 9 public comments that were relevant to the theme that was included by that reviewer, these sections were discussed, and a consensus was reached on the final applicable theme(s). The adjudication process resulted in the addition of 5 thematic codes to 5 of the 33 randomly selected public comments (1 change to each of the 5 public comments) across the total possible 165 codes (97% agreement).
Theme 1: Criteria for selecting the sIRB
Although the draft policy included an outline of responsibilities for participating centers and the sIRB, 31% (32) of the 102 respondents who had questions or suggestions indicated that the final policy should include specific selection criteria or a set of minimum requirements that may be applied to assess suitability to serve as the sIRB. Ensuring that the sIRB upholds certain quality standards was considered important. There are, however, no corresponding criteria for measuring the quality of IRB reviews short of the criteria applied for Human Research Protection Program (HRPP) accreditation by organizations such as the Association for the Accreditation of Human Research Protection Programs. [13] [14] [15] Commenters supported the use of HRPP accreditation as a criterion but were concerned that the cost of accreditation would be prohibitive for some institutions and that the current standards do not specifically address requirements for sIRB review in the multicenter study setting.
Several other selection criteria were suggested for inclusion in the final policy:
• History of compliance with federal policy on human participant protections;
• Number of types of IRBs, including convened disease-or topic-specific IRBs;
• Qualifications of IRB members, including therapeutic expertise;
• Experience serving as an sIRB or collaborating with other IRBs;
• Operational metrics (e.g., review time, frequency of meetings);
• Systems and programs used to track and document the review process; and
• Staffing (i.e., number, availability, and expertise of staff supporting the work of the HRPP).
In the final NIH policy, the investigator submitting the application to the NIH is tasked with ensuring that the IRB selected to serve as the sIRB is qualified, but guidance on selecting the sIRB was not included. 6 Subsequent to issuance of the final policy, the NIH Office of Science Policy posted a listing of sIRB policy frequently asked questions (FAQs), including a question on considerations for the selection of the sIRB. IRB history, experience, appropriateness, and expertise for the specific study under review as well as registration with the Office for Human Research Protection (OHRP) were considerations included in the response. 16 Additional guidance was not provided before the effective date.
Theme 2: Delineation of responsibilities: IRBs, institutions, and investigators
Thirty-eight percent (39/102; 38%) of those respondents with questions or suggestions commented on the lack of guidance on delineation of responsibilities in the draft NIH policy. Specific domains considered important to address included:
• State and local laws and other local context considerations-what will local IRBs provide, and how is the sIRB monitored for compliance;
• Conflicts of interest and investigator noncompliance with federal regulations as well as other reviews typically conducted by the local IRB; and
• Communication plans in general and plans specifically addressing adverse event reporting.
Per the NIH draft and final policies, each participating institution in the study in question must complete an IRB authorization agreement with the sIRB. The agreement should include the roles and responsibilities of participating entities and a process for the sIRB to collect and review local and state laws pertinent to the participating institutions.
6,9
The negotiation of authorization agreements can be time consuming and may obviate the expected gains in efficiency that are proposed with the policy. 5, 12 As a potential solution, commenters recommended that the NIH include guidance on delineation of responsibilities coupled with a template IRB authorization agreement.
In the final policy, the roles and responsibilities of the investigator (awardee), sIRB, and participating centers were outlined. 6 The principal investigator is responsible for ensuring that the sIRB and the participating centers establish a plan to communicate and must also ensure that all authorization agreements are executed. The sIRB is responsible for ethical review as per the federal regulatory requirements. A commenter suggested that the sIRB could serve as the Health Insurance Portability and Accountability Act Privacy Board, and this suggestion was adopted in the final policy. Domestic centers participating in an NIH-funded multicenter study are expected to use the sIRB for meeting the requirement for ethical review. Participating centers are expected to consent participants, administer the study protocol, and provide information on related local cultural and environmental issues, state and local laws, and studyrelated adverse events to the sIRB.
The NIH expects to provide a model communication plan, further guidance on roles and responsibilities, and materials to inform the collection and evaluation of local norms and laws prior to the policy's effective date. 6 The NIH's FAQs on implementation of the policy referenced two template IRB authorization agreements: a basic agreement prepared by the OHRP and a second by the NIH's National Center for Advancing Translational Sciences-the Streamlined, Multisite Accelerated Resources for Trials IRB Reliance Platform.
17,18
Theme 3: The cost of sIRB review
In the draft policy, the NIH proposed the inclusion of direct costs for sIRB review, but only for fee-based (independent) IRBs. Under the draft policy, no additional funds would be available to support sIRB review for academic institutions because these institutions include operating costs for IRBs in the facilities and administrative (F&A) rate, also known as indirect costs. Additional funding would be needed to support modifications to infrastructure and staffing to accommodate sIRB review as well as to support the conduct of initial and continuing review by the sIRB. Twenty-six percent (27/102; 26%) of respondents who had questions or suggestions about the policy noted that funding of non-fee-based IRBs was excluded from the draft NIH policy. There were calls for additional funding in the form of direct costs to support the establishment of the sIRB and to support related review activities. As stated among the comments, the draft policy on costs might have in fact resulted in an increase in the number of independent IRBs or made independent IRBs the only feasible option for the sIRB. 5 The final policy states that additional sIRB-related costs may be charged as direct costs, but must be justified; additional guidance suggests that there are limitations to what may be included in the budget. The NIH released guidance on how to include costs in the budget using scenarios where the awardee, the proposed sIRB, and/or categories of participating centers vary, and in January 2017, the NIH's Office of Policy for Extramural Research Administration prepared an FAQ that further defines how costs may be applied. 19, 20 Single-IRB-related activities are divided into primary and secondary activities. Primary activities are those specific to conducting the review itself, including review of the consent form. With a few exceptions, primary activities are considered a part of the institution's F&A cost rate routinely applied to all budgets. Costs related to modifications or additions to IRB and institutional data systems and other processes as well as additional personnel to accommodate sIRB review are also considered part of F&A costs-that is, there is no other NIH funding mechanism to support infrastructure expansion. Secondary activities are those related to the review of center-specific information, including local and state laws, other local considerations, and the review of unanticipated events, protocol deviations, and communications related to any disclosures during the course of the study. Secondary activities may be applied to the budget as direct costs and must be justified. Direct costs may be included to support study-specific administrative tasks provided that the investigator can justify that these tasks are essential to the project. All costs for independent IRBs that do not have an indirect cost agreement with the federal government and are unaffiliated with an academic institution may be charged as direct costs.
Theme 4: Consideration of local IRB reviews
The NIH draft and final policies state that the IRBs of participating centers are not precluded from conducting local IRB review, but institutions cannot use NIH funds to support the review. Fourteen percent (14/102; 14%) of respondents with questions or suggestions commented that the resolution of issues that are raised by the local IRBs that are not identified by or are in conflict with the sIRB had not been addressed. Although not directly advocating for local IRB review under the sIRB model, academic institutional stakeholders did express concern that an sIRB could not possibly consider all of the institutional considerations and center-specific practices for the participating centers. Commenters noted that local IRBs are better poised for this portion of ethical review because their memberships are knowledgeable of protections relevant to the population and could more readily identify investigator conflicts of interest.
Theme 5: Exceptions to the sIRB policy
In the draft policy, exceptions to the sIRB policy would be allowed "only if the designated sIRB is unable to meet the needs of specific populations or where local IRB review is required by federal, tribal, or state laws or regulations." 9 Other exceptions would be considered with justification. Nineteen percent (19/102; 19%) of respondents with questions or suggestions commented on the need to broaden the exceptions to the policy and proposed additional exceptions. These exceptions included specifying the vulnerable populations to whom this exception would apply, allowing institutional IRB chairpersons to decide whether the sIRB model is appropriate, allowing accredited HRPPs to opt out of the sIRB policy, and establishing criteria based on the type of study and/ or a minimum number of participating centers. The final policy statement on exceptions, however, is virtually unchanged from the draft policy.
Discussion
Dr. Carrie Wolinetz, associate director of the NIH Office of Science Policy, issued a statement to coincide with the release of the public comments in June 2015. Dr. Wolinetz estimated that 70% of the commenters supported the use of sIRBs for multicenter research-very similar to our findings (65%). 21, 22 The Council on Government Relations examined public comments submitted for the corresponding sIRB policy in the Common Rule and concluded that 42% of the commenters supported the proposed policy. 23 Although there is overall support for the NIH policy, comments, clarifications, and proposals for changes to the draft policy were submitted by a large percentage of respondents (61% of the total responses received; 49% from those supporting the policy). Dr. Wolinetz noted that there were many opposing responses to the draft policy on sIRB review; we agree with this assertion. 21 While the respondents highlighted several common challenges to the implementation of sIRB review, corresponding recommendations revealed a lack of consensus on the approach to sIRB review. At the time of the release of the public comments Dr. Wolinetz stated that the comments would be used to identify areas where additional guidance is necessary.
Included with the final NIH policy a year later was a discussion of the public comments on topics such as the categories of studies affected by the policy, suggestions for exceptions to the policy, the ability of sIRBs to consider local standards and laws, the importance of outlining the responsibilities of the IRB and the institution, criteria for selecting the sIRB, cost, and the need for guidance on implementation of the policy. 6 The NIH did use the public comments as a conduit for minor modifications, points of clarification, and identifying additional documents and guidance needed prior to implementation. Concurrent guidance on the application of costs for supporting sIRB review was released, and additional guidance on several topics was promised to address concerns regarding selection of the sIRB, roles and responsibilities, written agreements among the participating IRBs, and the collection of local laws and community norms for sIRB review. Subsequent to issuance of the final policy, the NIH Office of Science Policy posted FAQs on implementation of the policy and costs that addressed some of the topics that were promised for future guidance, but as of March 2018, no additional documents had been released. 16, 20 There was consensus from the public comments on one issue-implementation would not be seamless, and a lack of crucial details and guidance from the NIH could delay efforts to prepare for sIRB review by the effective policy date. And in effect, the NIH has had to delay the effective date of the policy twice. The initial effective date was May 2017. In December 2016, this date was extended to September 25, 2017 , and in June 2017, the date was extended again to January 25, 2018-a sign that implementation is more cumbersome and complicated than anticipated.
It is clear from the NIH's response in the final policy as well as subsequent guidance released that there are several outstanding issues that must be addressed, and the NIH noted plans to address many issues before the policy's effective date. By far the most comprehensive guidance has been on applicable costs, but many affected institutions cannot accurately estimate actual costs. There are limited data on study-specific, IRB, and institutional personnel and infrastructure costs that could be leveraged from existing sIRBs to provide estimates of cost. Concerns and resistance will mount if costs are exorbitant and not reimbursable by current NIH standards.
The delineation of regulatory and other responsibilities of participating institutions, IRBs, and investigators has been addressed in the final NIH policy, and these additions are important because they clearly establish the role of each entity in the regulatory process. The NIH referenced two IRB authorization documents to assist with the delineation of responsibilities, but given the varied risk profiles of studies that fall under the new policy, further negotiations will likely be necessary to address issues unique to each study. In particular, indemnification is not addressed in existing authorization agreements, and institutions will need to negotiate this separately. To be most efficient, there also should be stakeholder consensus on the language of any authorization agreements and a requirement to use the agreement without appreciable modifications. We also note that new regulations regarding issues of IRB regulatory noncompliance are included in the revised federal policy (Common Rule, effective July 19, 2018). 24 In the federal policy, findings of regulatory noncompliance would be addressed with the sIRB conducting the review instead of the institutions relying on the review. 24 Presently, noncompliance by the reviewing IRB could affect all institutions involved in the study. This content analysis is limited by our interpretation of each public comment. Independent review by a second researcher was included as a measure of agreement on the identification of the themes discussed, and agreement among the reviewers was high. This manuscript is also limited to four themes that were prespecified and a fifth theme that emerged from the open text review of the comments, as it was not feasible to discuss all issues highlighted by commenters. Several other issues were discussed in the public comments, such as requests for additional empirical evidence on the utility of sIRB review and the need for harmonization of federal policies on sIRB review. However, we chose to focus on themes that were specific to implementation of the policy because these are the issues that might have the greatest impact on institutions preparing to comply with the NIH policy.
As highlighted by the respondents to the NIH draft policy, many knowledge gaps remain, and empirical data are needed to guide implementation of the policy. 12 Process metrics for various models of sIRB review exist but are not published. 7 Cost and impact analyses are necessary to assess the utility of sIRB review. More clarity on the information that sIRBs require to assess local laws and cultural norms is crucial. 25 The NIH issued two announcements for the funding of empirical research on sIRBs, but hopefully there will be additional funding available for studies of IRB metrics and operating procedures as well as an impact analysis to assess how the change in policy affects institutions, investigators, and other stakeholders. The NIH is providing supplemental funding for participants in the Clinical and Translational Science Awards program only to develop resources and infrastructure to support sIRB implementation. Supplemental funding awardees will share their findings with the NIH in 2019, and the NIH will disseminate this information once available. 26 The NIH is also considering mechanisms to support the advancement of models for assessing cost and other procedures and processes to establish best practices for facilitating the implementation of sIRB review. 22, 27 The NIH made a concerted effort to incorporate public feedback in the development of its sIRB policy. Public comments informed modifications to the draft policy and also demonstrated many opportunities for guidance on implementation of the policy. While some problems with the NIH policy remain, public comments were effective in shaping the final policy.
